טוען...
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
BACKGROUND: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a d...
שמור ב:
| הוצא לאור ב: | Respir Res |
|---|---|
| Main Authors: | , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2021
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094468/ https://ncbi.nlm.nih.gov/pubmed/33947414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01714-y |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|